<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534818</url>
  </required_header>
  <id_info>
    <org_study_id>2015SDU-QILU-G09</org_study_id>
    <nct_id>NCT02534818</nct_id>
  </id_info>
  <brief_title>Different Fluorescein Sodium Dosage for the Detection of Gastric Intestinal Metaplasia</brief_title>
  <official_title>Conventional Fluorescein Sodium Dosage o.1ml/kg Compared With a Lower Fluorescein Sodium Dosage o.02ml/kg for the Detection of Gastric Intestinal Metaplasia in a High Risk Population: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether lower fluorescein sodium dosage can perceive
      the same detection rate per patient and per lesion for the detection of gastric intestinal
      metaplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric intestinal metaplasia is regarded as an important premalignant lesion for intestinal
      type gastric cancer. Currently, the histological assessment of gastric intestinal metaplasia
      still relies on the biopsies took from five sites that the updated Sydney System recommended.

      This study aims to compare the diagnostic yield of gastric intestinal metaplasia from two
      different fluorescein sodium dosage and assess whether lower fluorescein sodium dosage can
      perceive the same detection rate per patient and per lesion for the detection of gastric
      intestinal metaplasia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of the detection rate of gastric intestinal metaplasia between two fluosecein sodium dosage in a per-pateint analysis</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference of the detection rate of gastric intestinal metaplasia between two dosage fluosecein sodium in a per-biopsy analysis</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Gastric Intestinal Metaplasia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lower fluorescein sodium dosage 0.02ml/kg for gastric intestinal metapalsia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional fluorescein sodium dosage 0.1ml/kg for gastric intestinal metapalsia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lower fluorescein sodium dosage 0.02ml/kg</intervention_name>
    <description>fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conventional fluorescein sodium dosage 0.1ml/kg</intervention_name>
    <description>fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with dyspeptic symptoms and aged 40 years or older

          -  or patients with Helicobacter pylori infection, or histologically verified gastric
             intestinal metaplasia or atrophic gastritis

          -  or patients with family history of gastric cancer

        Exclusion Criteria:

          -  presence of gastrectomy, acute gastrointestinal bleeding, or known gastric neoplasia

          -  presence of conditions unsuitable for endoscopy procedure including coagulopathy,
             impaired cardiopulmonary function , pregnancy or breastfeeding

          -  inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanqing Li, PhD. MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Gastroenterology, Qilu Hospital, Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanqing Li, PhD. MD</last_name>
    <phone>18678827666</phone>
    <phone_ext>82169508</phone_ext>
    <email>qiluliyanqing@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology, Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqing Li, MD, PhD</last_name>
      <phone>86-531-82169236</phone>
      <phone_ext>82169508</phone_ext>
      <email>liyanqing@sdu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>November 7, 2015</last_update_submitted>
  <last_update_submitted_qc>November 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Yanqing Li</investigator_full_name>
    <investigator_title>Vice president of Qilu Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

